JP2020504136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504136A5 JP2020504136A5 JP2019536863A JP2019536863A JP2020504136A5 JP 2020504136 A5 JP2020504136 A5 JP 2020504136A5 JP 2019536863 A JP2019536863 A JP 2019536863A JP 2019536863 A JP2019536863 A JP 2019536863A JP 2020504136 A5 JP2020504136 A5 JP 2020504136A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutical composition
- azaspiro
- cancer
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 87
- 229940000425 combination drug Drugs 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 201000011510 cancer Diseases 0.000 claims description 72
- -1 5-((6-amino-2,3-dichloropyridin-4-yl) thio) pyrazine-2-yl Chemical group 0.000 claims description 25
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 21
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 17
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 16
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 16
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical group CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 8
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 229960001602 ceritinib Drugs 0.000 claims description 4
- JYRWFZZKEKTMSK-UHFFFAOYSA-N decan-4-amine Chemical compound CCCCCCC(N)CCC JYRWFZZKEKTMSK-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000006845 reticulosarcoma Diseases 0.000 claims description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 claims description 3
- 208000024305 myofibroblastoma Diseases 0.000 claims description 3
- XDODTCSHMOQQKP-GXTWGEPZSA-N (2R,4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=CN=C(SC2=CC=NC(N)=C2Cl)C=N1 XDODTCSHMOQQKP-GXTWGEPZSA-N 0.000 claims description 2
- QRCMRHHVLLNDAD-WCQYABFASA-N (2R,4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(C[C@H](C[C@H]2N)C)CC1)SC1=C(C(=NC=C1)N)Cl QRCMRHHVLLNDAD-WCQYABFASA-N 0.000 claims description 2
- FDSVUVZQRZMZJD-MGPLVRAMSA-N (3S,4S)-8-[3-(2,3-dichloropyridin-4-yl)-2H-pyrazolo[3,4-b]pyrazin-6-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound ClC1=NC=CC(=C1Cl)C1=NNC2=NC(=CN=C21)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1 FDSVUVZQRZMZJD-MGPLVRAMSA-N 0.000 claims description 2
- MQHUNAGZKZJLQU-APPDUMDISA-N (3S,4S)-8-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C1=C(C(=CC=C1)Cl)Cl MQHUNAGZKZJLQU-APPDUMDISA-N 0.000 claims description 2
- BSPKRXNBXSLYTO-XHDPSFHLSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-ethyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2([C@@H]([C@@H](OC2)CC)N)CC1)SC1=C(C(=NC=C1)N)Cl BSPKRXNBXSLYTO-XHDPSFHLSA-N 0.000 claims description 2
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 claims description 2
- OVNZJLIYRSOHHB-RGUGMKFQSA-N (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound CC1CCC2(CCN(CC2)C2=CN=C(SC3=CC=NC(N)=C3Cl)C=N2)[C@@H]1N OVNZJLIYRSOHHB-RGUGMKFQSA-N 0.000 claims description 2
- CQASZSQCUYWGME-CYBMUJFWSA-N (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=NC=CC(=C1Cl)SC=1N=CC(=NC=1)N1CCC2(CCC[C@H]2N)CC1 CQASZSQCUYWGME-CYBMUJFWSA-N 0.000 claims description 2
- DYZZCXHBYCBNEC-CQSZACIVSA-N (4R)-8-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)C1=C(C(=CC=C1)Cl)Cl DYZZCXHBYCBNEC-CQSZACIVSA-N 0.000 claims description 2
- DIFDDGZESHEIPC-JOPIAHFSSA-N (4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-8-azaspiro[4.5]decan-4-amine Chemical compound CC1CCC2(CCN(CC2)C2=CN=C(SC3=CC=NC(N)=C3Cl)C(N)=N2)[C@@H]1N DIFDDGZESHEIPC-JOPIAHFSSA-N 0.000 claims description 2
- YXXCYOPEUVHPLV-GFCCVEGCSA-N (4R)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)SC1=C(C(=NC=C1)N)Cl YXXCYOPEUVHPLV-GFCCVEGCSA-N 0.000 claims description 2
- ILINPAZQNCUDMW-CYBMUJFWSA-N (4R)-8-[6-amino-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=NC=CC=1)C(F)(F)F ILINPAZQNCUDMW-CYBMUJFWSA-N 0.000 claims description 2
- AHSZEDCSMMKDNF-GFCCVEGCSA-N (4S)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound N[C@@H]1COCC11CCN(CC1)C1=CN=C(SC2=CC=NC(N)=C2Cl)C=N1 AHSZEDCSMMKDNF-GFCCVEGCSA-N 0.000 claims description 2
- OMJHHTRDBKAMSN-LLVKDONJSA-N (4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound N[C@@H]1COCC11CCN(CC1)C1=CN=C(SC2=CC=NC(N)=C2Cl)C(N)=N1 OMJHHTRDBKAMSN-LLVKDONJSA-N 0.000 claims description 2
- HRZBBEFONKKGFY-GFCCVEGCSA-N (4S)-8-[6-amino-5-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound NC1=C(N=CC(=N1)N1CCC2([C@@H](COC2)N)CC1)SC=1C(=NC=CC1)C(F)(F)F HRZBBEFONKKGFY-GFCCVEGCSA-N 0.000 claims description 2
- HZDHVNNLNPUGCB-UHFFFAOYSA-N 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1NC(C2=C(N=1)NC=C2C1=C(C(=CC=C1)Cl)Cl)=O)C HZDHVNNLNPUGCB-UHFFFAOYSA-N 0.000 claims description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims description 2
- MLZSINIGJFDNQZ-UHFFFAOYSA-N 6-(1,8-diazaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound ClC1=C(C=CC=C1Cl)C=1C(=NC(=CN=1)N1CCC2(CCCN2)CC1)N MLZSINIGJFDNQZ-UHFFFAOYSA-N 0.000 claims description 2
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 claims description 2
- PXWVEUAMAFDBCT-SWLSCSKDSA-N 6-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-3-(6-amino-2-methylpyridin-3-yl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)c1nc2n[nH]c(-c3ccc(N)nc3C)c2c(=O)n1C PXWVEUAMAFDBCT-SWLSCSKDSA-N 0.000 claims description 2
- URUPFUYPXLMTMT-KPZWWZAWSA-N 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-[3-chloro-2-(cyclopropylamino)pyridin-4-yl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@@H]1OCC2(CCN(CC2)c2nc3n[nH]c(-c4ccnc(NC5CC5)c4Cl)c3c(=O)n2C)[C@@H]1N URUPFUYPXLMTMT-KPZWWZAWSA-N 0.000 claims description 2
- JLWLVSCZOWTUQJ-CYBMUJFWSA-N 6-[(4R)-4-amino-2,2-difluoro-8-azaspiro[4.5]decan-8-yl]-3-(6-amino-2-methylpyridin-3-yl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound NC1=CC=C(C(=N1)C)C=1NN=C2N=C(N(C(C2=1)=O)C)N1CCC2(CC(C[C@H]2N)(F)F)CC1 JLWLVSCZOWTUQJ-CYBMUJFWSA-N 0.000 claims description 2
- AWCUGJTVKPBYHS-CQSZACIVSA-N 6-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1N(C(C=2C(N=1)=NNC=2C1=C(C(=CC=C1)Cl)Cl)=O)C AWCUGJTVKPBYHS-CQSZACIVSA-N 0.000 claims description 2
- ZAMNYDQBNJFTSZ-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound CC1(CN)CCN(CC1)C1=CN=C(C(N)=N1)C1=CC=CC(Cl)=C1Cl ZAMNYDQBNJFTSZ-UHFFFAOYSA-N 0.000 claims description 2
- JBLYMVJAFCDNOA-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-[2-(trifluoromethyl)pyridin-3-yl]sulfanylpyrazin-2-amine Chemical compound NCC1(CCN(CC1)C1=CN=C(C(=N1)N)SC=1C(=NC=CC1)C(F)(F)F)C JBLYMVJAFCDNOA-UHFFFAOYSA-N 0.000 claims description 2
- YFMXXMJLAJOQKJ-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-phenylpiperidin-1-yl]-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NCC1(CCN(CC1)C1=CN=C(C(N)=N1)C1=CC=CC(Cl)=C1Cl)C1=CC=CC=C1 YFMXXMJLAJOQKJ-UHFFFAOYSA-N 0.000 claims description 2
- LNQYLYAZNKGMBQ-GOEBONIOSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-3-methyl-5-phenylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C2=CC=CC=C2)C(=O)N1C LNQYLYAZNKGMBQ-GOEBONIOSA-N 0.000 claims description 2
- XNRBIYGXCHMMLM-SWLSCSKDSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-3-methylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C(=O)N1C)C1=CC=CC(Cl)=C1Cl XNRBIYGXCHMMLM-SWLSCSKDSA-N 0.000 claims description 2
- IKKUGOCAYJSNOZ-XJKSGUPXSA-N 6-amino-2-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-5-(4-chlorophenyl)-3-methylpyrimidin-4-one Chemical compound C[C@H]1C[C@@H](N)C2(C1)CCN(CC2)C1=NC(N)=C(C2=CC=C(Cl)C=C2)C(=O)N1C IKKUGOCAYJSNOZ-XJKSGUPXSA-N 0.000 claims description 2
- NYPXMXPABWAYNI-UHFFFAOYSA-N CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4CCCCn4c3=O)c2Cl)c(N)n1 Chemical compound CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4CCCCn4c3=O)c2Cl)c(N)n1 NYPXMXPABWAYNI-UHFFFAOYSA-N 0.000 claims description 2
- SXLOCFFGRYJKJH-UHFFFAOYSA-N CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4ccccn4c3=O)c2Cl)c(N)n1 Chemical compound CC1(CN)CCN(CC1)c1cnc(Sc2cccc(NC(=O)c3c(O)nc4ccccn4c3=O)c2Cl)c(N)n1 SXLOCFFGRYJKJH-UHFFFAOYSA-N 0.000 claims description 2
- JBTYRLRPDPSWAY-UHFFFAOYSA-N N-[3-[3-amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl]sulfanyl-2-chlorophenyl]-3-hydroxy-5-oxo-1-phenyl-2H-pyrrole-4-carboxamide Chemical compound CC1(N)CCN(CC1)c1cnc(Sc2cccc(NC(=O)C3=C(O)CN(C3=O)c3ccccc3)c2Cl)c(N)n1 JBTYRLRPDPSWAY-UHFFFAOYSA-N 0.000 claims description 2
- QQGWBWWGXPNCEH-UHFFFAOYSA-N NC=1C(=NC=C(N=1)N1CCC(CC1)(CF)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC(CC1)(CF)N)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl QQGWBWWGXPNCEH-UHFFFAOYSA-N 0.000 claims description 2
- PVBNSTQJFPASQY-QGZVFWFLSA-N NC=1C(=NC=C(N=1)N1CCC2(CC(C[C@H]2N)(F)F)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC2(CC(C[C@H]2N)(F)F)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl PVBNSTQJFPASQY-QGZVFWFLSA-N 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 229950001290 lorlatinib Drugs 0.000 claims description 2
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- QZVSNMBRLYUYQI-GOSISDBHSA-N NC=1C(=NC=C(N=1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl Chemical compound NC=1C(=NC=C(N=1)N1CCC2(CCC[C@H]2N)CC1)SC=1C(=C(C=CC=1)NC(=O)C1=C(N=C2N(C1=O)CCCC2)O)Cl QZVSNMBRLYUYQI-GOSISDBHSA-N 0.000 claims 1
- SJVCCJDLEIGCAW-QGZVFWFLSA-N N[C@@H]1COCC11CCN(CC1)C1=NC(N)=C(SC2=CC=CC(NC(=O)C3=C(O)N=C4CCCCN4C3=O)=C2Cl)N=C1 Chemical compound N[C@@H]1COCC11CCN(CC1)C1=NC(N)=C(SC2=CC=CC(NC(=O)C3=C(O)N=C4CCCCN4C3=O)=C2Cl)N=C1 SJVCCJDLEIGCAW-QGZVFWFLSA-N 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 1
- JJTYMCPMKUFMGA-UHFFFAOYSA-N N-[3-[3-amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl]sulfanyl-2-chlorophenyl]-2-benzyl-3-hydroxy-1-methyl-5-oxo-2H-pyrrole-4-carboxamide Chemical compound CN1C(Cc2ccccc2)C(O)=C(C(=O)Nc2cccc(Sc3ncc(nc3N)N3CCC(C)(N)CC3)c2Cl)C1=O JJTYMCPMKUFMGA-UHFFFAOYSA-N 0.000 description 1
- ZVBSVBHUEYAOGL-UHFFFAOYSA-N Nc1nc(cnc1Sc1cccc(NC(=O)c2c(O)nc3ccccn3c2=O)c1Cl)N1CCC(N)(CF)CC1 Chemical compound Nc1nc(cnc1Sc1cccc(NC(=O)c2c(O)nc3ccccn3c2=O)c1Cl)N1CCC(N)(CF)CC1 ZVBSVBHUEYAOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022142153A JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444493P | 2017-01-10 | 2017-01-10 | |
| US62/444,493 | 2017-01-10 | ||
| PCT/IB2018/050111 WO2018130928A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142153A Division JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504136A JP2020504136A (ja) | 2020-02-06 |
| JP2020504136A5 true JP2020504136A5 (enExample) | 2021-02-04 |
| JP7503380B2 JP7503380B2 (ja) | 2024-06-20 |
Family
ID=61028108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536863A Active JP7503380B2 (ja) | 2017-01-10 | 2018-01-08 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
| JP2022142153A Pending JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022142153A Pending JP2022184886A (ja) | 2017-01-10 | 2022-09-07 | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190343836A1 (enExample) |
| EP (1) | EP3568204B1 (enExample) |
| JP (2) | JP7503380B2 (enExample) |
| KR (1) | KR102571130B1 (enExample) |
| CN (1) | CN110730678B (enExample) |
| AU (1) | AU2018207464B2 (enExample) |
| CA (1) | CA3048340A1 (enExample) |
| ES (1) | ES2964956T3 (enExample) |
| IL (1) | IL267617A (enExample) |
| RU (1) | RU2769132C2 (enExample) |
| WO (1) | WO2018130928A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MX388576B (es) * | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7447002B2 (ja) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| IL276232B2 (en) | 2018-03-02 | 2024-04-01 | Otsuka Pharma Co Ltd | Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| KR20210030411A (ko) | 2018-07-10 | 2021-03-17 | 사노피 | Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법 |
| MX2021000795A (es) * | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| CN112601750B (zh) | 2018-08-10 | 2023-10-31 | 纳维尔制药有限公司 | Ptpn11（shp2）抑制剂 |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN111153899B (zh) * | 2018-11-08 | 2023-12-01 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶化合物、其制备方法和用途 |
| EP3889153A4 (en) | 2018-11-30 | 2022-09-07 | Tuojie Biotech (Shanghai) Co., Ltd. | PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF |
| MX2021009562A (es) * | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| US20220152026A1 (en) * | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| EP3923941B1 (en) * | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and ribociclib |
| MX2021010319A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos biciclicos de heteroarilo y usos de estos. |
| MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| JP7586834B2 (ja) | 2019-04-08 | 2024-11-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｈｐ２拮抗薬としてのピリミジノン誘導体 |
| KR20220054285A (ko) | 2019-06-28 | 2022-05-02 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도 |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4069301A1 (en) * | 2019-12-04 | 2022-10-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| CN113135910A (zh) * | 2020-01-19 | 2021-07-20 | 北京诺诚健华医药科技有限公司 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
| TW202140024A (zh) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 |
| CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
| CN111393459B (zh) * | 2020-04-16 | 2022-07-22 | 南京安纳康生物科技有限公司 | Shp2抑制剂及其用途 |
| CA3179994A1 (en) * | 2020-05-08 | 2021-11-11 | Novartis Ag | Pharmaceutical combination comprising tno155 and nazartinib |
| WO2021236775A1 (en) * | 2020-05-19 | 2021-11-25 | The Regents Of The University Ofmichigan | Small molecule degraders of shp2 protein |
| CA3181898A1 (en) * | 2020-06-11 | 2021-12-16 | Bang Fu | Shp2 inhibitors, compositions and uses thereof |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| JP2023530838A (ja) * | 2020-06-22 | 2023-07-20 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用 |
| US12441737B2 (en) | 2020-07-08 | 2025-10-14 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022089389A1 (zh) * | 2020-10-30 | 2022-05-05 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
| CN112402385B (zh) * | 2020-11-30 | 2022-04-01 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
| CN112194652B (zh) * | 2020-11-30 | 2021-03-05 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
| JP7849366B2 (ja) | 2020-12-22 | 2026-04-21 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｓｏｓ１阻害剤およびその使用 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| IL308222A (en) | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| JP2024516997A (ja) | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| WO2023280237A1 (zh) * | 2021-07-07 | 2023-01-12 | 海创药业股份有限公司 | 一种磷酸酶降解剂的合成和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20230106506A (ko) * | 2022-01-03 | 2023-07-13 | 한국생명공학연구원 | Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물 |
| TW202342040A (zh) * | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202542151A (zh) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| CN120227378A (zh) * | 2023-12-28 | 2025-07-01 | 轩竹生物科技股份有限公司 | 间变性淋巴瘤激酶抑制剂的药物组合物及其制备方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| WO1987004928A1 (fr) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| DK169008B1 (da) | 1990-06-01 | 1994-07-25 | Holec Lk A S | Fremgangsmåde og skærm til afskærmning af en strømtransformer samt strømtransformer med en sådan afskærmning |
| AU4198400A (en) | 1999-04-06 | 2000-10-23 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| ATE407678T1 (de) | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| GB0300783D0 (en) | 2003-01-14 | 2003-02-12 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| WO2005095384A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| CA2622372A1 (en) | 2005-09-13 | 2007-03-22 | Palau Pharma, S.A. | 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity |
| WO2007112368A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| US7515405B2 (en) | 2006-07-25 | 2009-04-07 | Hewlett-Packard Development Company, L.P. | Anti-rotation mechanism for an electronic device |
| US20090137549A1 (en) | 2006-11-09 | 2009-05-28 | Paul John Edward | Novel compounds useful for the treatment of degenerative & inflamatory diseases |
| EA017405B9 (ru) | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| US8252803B2 (en) | 2007-02-12 | 2012-08-28 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
| CA2681162C (en) | 2007-03-15 | 2015-11-24 | Novartis Ag | Benzyl and pyridine derivatives as modulators of hedgehog pathway |
| AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP2011522865A (ja) | 2008-06-13 | 2011-08-04 | ノバルティス アーゲー | Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物 |
| CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CN102356066A (zh) | 2008-12-10 | 2012-02-15 | 同和药品株式会社 | 新型2，6-取代的-3-硝基吡啶衍生物、其制备方法及包含有其的药物组合物 |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| NZ713361A (en) | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| ES2689103T3 (es) | 2010-06-30 | 2018-11-08 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
| JP2013531037A (ja) | 2010-07-13 | 2013-08-01 | メルク・シャープ・エンド・ドーム・コーポレイション | スピロ環式化合物 |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CA2813162C (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
| US9321760B2 (en) | 2011-09-12 | 2016-04-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| WO2013096093A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
| ES2751944T3 (es) * | 2012-05-23 | 2020-04-02 | Nerviano Medical Sciences Srl | Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida |
| CN104540830A (zh) | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| JP6099753B2 (ja) | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| WO2015050344A1 (ko) | 2013-10-01 | 2015-04-09 | 주식회사 엘지화학 | 도전성 적층체 |
| WO2015092819A2 (en) | 2013-12-21 | 2015-06-25 | Nektar Therapeutics (India) Pvt. Ltd. | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine |
| KR20160100975A (ko) * | 2013-12-23 | 2016-08-24 | 노파르티스 아게 | 제약 조합물 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| US10174032B2 (en) | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
| CN107207524B (zh) | 2014-08-15 | 2020-02-07 | 贵州省中国科学院天然产物化学重点实验室 | 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| US9296721B1 (en) * | 2015-02-13 | 2016-03-29 | Yong Xu | Method for preparing ALK inhibitor ceritinib |
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2018057884A1 (en) * | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) * | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
-
2018
- 2018-01-08 CA CA3048340A patent/CA3048340A1/en active Pending
- 2018-01-08 EP EP18701574.8A patent/EP3568204B1/en active Active
- 2018-01-08 ES ES18701574T patent/ES2964956T3/es active Active
- 2018-01-08 WO PCT/IB2018/050111 patent/WO2018130928A1/en not_active Ceased
- 2018-01-08 AU AU2018207464A patent/AU2018207464B2/en not_active Ceased
- 2018-01-08 KR KR1020197019305A patent/KR102571130B1/ko active Active
- 2018-01-08 US US16/475,982 patent/US20190343836A1/en not_active Abandoned
- 2018-01-08 RU RU2019120986A patent/RU2769132C2/ru active
- 2018-01-08 JP JP2019536863A patent/JP7503380B2/ja active Active
- 2018-01-08 CN CN201880006104.XA patent/CN110730678B/zh active Active
-
2019
- 2019-06-24 IL IL267617A patent/IL267617A/en unknown
-
2022
- 2022-04-06 US US17/714,996 patent/US12053470B2/en active Active
- 2022-09-07 JP JP2022142153A patent/JP2022184886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504136A5 (enExample) | ||
| JP2022184886A5 (enExample) | ||
| JP7503380B2 (ja) | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 | |
| US6432989B1 (en) | Use of CRF antagonists to treat circadian rhythm disorders | |
| US20050209250A1 (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
| US20010041673A1 (en) | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | |
| US10786492B2 (en) | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | |
| US20100009934A1 (en) | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders | |
| AU2013345107B2 (en) | Heteroaromatic compounds as PI3 kinase modulators and methods of use | |
| JP2016537384A5 (enExample) | ||
| JP2005500315A5 (enExample) | ||
| JP2004527560A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2013500247A5 (enExample) | ||
| AU2008276451A1 (en) | Treatments of B-cell proliferative disorders | |
| JP2004525149A5 (enExample) | ||
| JP2018529731A5 (enExample) | ||
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| JP2019528302A5 (enExample) | ||
| KR20130087058A (ko) | 피리미딜아미노벤즈아미드와 ｍｔｏｒ 키나제 억제제의 조합물 | |
| MXPA06009271A (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |